Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score by Amin Ussif, Hege Pihlstrøm, Andreas Pasch, Hallvard Holdaas, Anders Hartmann, Knut Smerud, Anders Åsberg

Get full text

Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study by Sadollah Abedini, MD, PhD, Lasse Gøransson, MD, PhD, Elinor Cockburn, MSc, PhD, Suzanne Kilany, BSc, Hallvard Holdaas, MD, PhD

Get full text

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. by Hege Kampen Pihlstrøm, Thor Ueland, Annika E Michelsen, Pål Aukrust, Franscesca Gatti, Clara Hammarström, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, Geir Mjøen, Dag Olav Dahle, Karsten Midtvedt, Ivar Anders Eide, Anders Hartmann, Hallvard Holdaas

Get full text

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary by Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström

Get full text